Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]
Muñoz Negrete FJ, Lemij HG, Erb C. Clinical Ophthalmology. 2017;11:557–566.On page 557, Abstract, the second sentence “This multicenter, international (Belgium, the Netherlands, and Spain), epidemiological convenience sample survey among patients commencing treatment w...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7e907fc557e04188902f4abe72e9f164 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Muñoz Negrete FJ, Lemij HG, Erb C. Clinical Ophthalmology. 2017;11:557–566.On page 557, Abstract, the second sentence “This multicenter, international (Belgium, the Netherlands, and Spain), epidemiological convenience sample survey among patients commencing treatment with preservative-free latanoprost collected data on patient satisfaction with particular regard to tolerability” should read “This multicenter, international (Germany, the Netherlands, and Spain), epidemiological convenience sample survey among patients commencing with preservative-free latanoprost collected data on patient satisfaction with particular regard to tolerability”.On page 558, Methods section, Inclusion criteria subheading, 1st sentence, the drug name Monoprost® should have been Monopost®.On page 559, Methods section, Analysis of variables subheading, 2nd paragraph, 1st sentence, the drug name Monoprost® should have been Monopost®.Read the original article |
|---|